Latest News

Coming ever closer – first PARP inhibitor licensed in Europe

Designed to target cancers in people carrying inherited faults in the BRCA1 or BRCA2 genes, PARP inhibitors have been tested in clinical trials for patients with breast, ovarian and prostate cancer caused by these genetic flaws. However, the journey from the lab to the clinic has been far from smooth, and the results have been […]

Read More